Maurice Pérol
Maurice Pérol is an expert in Oncology at Centre Léon Bérard (France). As of October 2026, ScienceLeadR ranks Maurice Pérol in the top 1% of experts worldwide for Lung Neoplasms, Bronchial Neoplasms and Thoracic Neoplasms. Maurice Pérol has authored 604 publications, the most recent in 2026, and is an investigator in 62 clinical trials, 24 of them ongoing. SLR score: 2,765 (community average: 125). How the SLR is computed.
LeadR Profile
Oncology
Subspecialties: Pulmonology - Immunology - Public Health
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1989 - 2026
Number : 604
Citations
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Tarlatamab-Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer. PMID 42929702 — cells, lung, progression-free survival, neoplasms, maintenance, lung neoplasms, small cell lung carcinoma, therapeutics, ligands | N Engl J Med Top journal | 2026 | 0 |
| Fusion isoform multiplicity and impact on treatment outcomes in ALK-rearranged non-small cell lung cancer with next-generation tyrosine kinase inhibitors. PMID 42691832 — cells, lung, protein isoforms, neoplasms, carcinoma, non-small-cell lung, lung neoplasms, small cell lung carcinoma, protein-tyrosine kinases, tyrosine, therapeutics | Lung Cancer | 2026 | 0 |
| Dissociated skeletal response to first-line immunotherapy in synchronous bone metastatic non-small cell lung cancer patients: Clinical profiles and survival benefit of denosumab adjunction. PMID 42662853 — cells, lung, progression-free survival, neoplasms, carcinoma, non-small-cell lung, immunotherapy, denosumab, lung neoplasms, small cell lung carcinoma, sex, therapeutics, tissues, mutation | J Bone Oncol | 2026 | 0 |
| Treatment patterns and outcomes in advanced and metastatic lung cancer in France: Results from the Epidemiological Strategy and medical Economics (ESME) database lung cancer in France. PMID 42660015 — cells, lung, neoplasms, carcinoma, non-small-cell lung, economics, medical, lung neoplasms, therapeutics, economics | Lung Cancer | 2026 | 0 |
| Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial. PMID 42636833 — cells, lung, safety, stroke, progression-free survival, neoplasms, disease progression, carcinoma, non-small-cell lung, drug therapy, drug-related side effects and adverse reactions, lung neoplasms, small cell lung carcinoma, protein-tyrosine kinases, tyrosine, therapeutics, chemotherapy | Lancet Oncol Top journal | 2026 | 4 |
Clinical Studies 62
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Cohort/Consortium Investigators 1
Ongoing Clinical Trials
24 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases 2023-507494-18-00 — oncogenes, proto-oncogenes, cells, genes, lung, receptor protein-tyrosine kinases, safety, neoplasms, gene rearrangement, carcinoma, non-small-cell lung, central nervous system, lung neoplasms, neoplasm metastasis, small cell lung carcinoma, protein-tyrosine kinases, tyrosine, therapeutics, nervous system, crizotinib | Phase 3 | Active not recruiting | 2021 |
| A Study to Test How Well ZL 1310 may Work Compared to Therapies Selected by the Investigator in Treating Patients with Relapsed Small Cell Lung Cancer 2025-522818-23-00 — cells, lung, pharmaceutical preparations, neoplasms, lung neoplasms, small cell lung carcinoma, work, therapeutics | Phase 3 | Not yet recruiting | 2026 |
| A Randomized Double Blind Placebo Controlled MultiRegional Phase III Clinical Study of Toripalimab Alone or in Combination With Tifcemalimab (JS004 TAB004) as Consolidation Therapy in Patients With Limited Stage Small Cell Lung Cancer Without Disease Progression Following Chemoradiotherapy 2023-507097-41-01 — cells, lung, neoplasms, disease progression, multiple chronic conditions, lung neoplasms, chemoradiotherapy, small cell lung carcinoma, therapeutics | Phase 3 | Active not recruiting | 2025 |
| Study of pre and post surgery treatment with IPH5201 and durvalumab in participants with lung cancer (MATISSE) 2023-507778-42-00 — cells, lung, neoplasms, carcinoma, non-small-cell lung, lung neoplasms, small cell lung carcinoma, neoadjuvant therapy, therapeutics | Phase 2 | Recruiting | 2023 |
| Beamion 44 A study to test how well zongertinib is tolerated by people with advanced non small cell lung cancer with HER2 mutations when given in combination with chemotherapy with or without pembrolizumab 2025-523567-38-00 — cells, lung, safety, neoplasms, multiple chronic conditions, carcinoma, non-small-cell lung, drug therapy, lung neoplasms, small cell lung carcinoma, therapeutics, mutation, chemotherapy, her2 mutation | Phase 2 | Recruiting | 2026 |
LeadR Networks
Main global connection map